Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE–Latin America study

References

• IDF. Diabetes Atlas 2012. Available at: www.idf.org/diabetesatlas. Last accessed 05 June 2014
   Google Scholar
• Barcelo A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003;81:19-27
   PubMed Web of Science ®Google Scholar
• Pedersen O, Gaede P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism 2003;52:19-23
   PubMed Web of Science ®Google Scholar
• Ali MK, McKeever-Bullard K, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Eng J Med 2013;368:1613-24
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ, Chiquete E, de la Luz J, et al.; IDMPS-3W collaborative group (Mexico). Achievement of therapeutic targets in Mexican patients with diabetes mellitus. Endocrinol Nutr 2012;59:591-8
   PubMedGoogle Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009;62:499-505
   PubMed Web of Science ®Google Scholar
• Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009;10:37
   PubMed Web of Science ®Google Scholar
• Ware JH, Hamel MB. Pragmatic trials – guides to better patient care? N Engl J Med 2011;364:1685-7
   PubMed Web of Science ®Google Scholar
• Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 2013;67:947-56
   Google Scholar
• Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
   PubMed Web of Science ®Google Scholar
• Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012;157:601-10
   PubMed Web of Science ®Google Scholar
• Luongo AM, López-González E, Garcia AB, et al.; en nombre del Grupo FRADYC. Evaluación del tratamiento de la Diabetes Tipo 2 realizado por especialistas en Argentina. Rev ALAD 2011;1:78-87
   Google Scholar
• Alvarenga RL, Molina JM, Góchez N, Rodríguez PA. Caracterización de pacientes que asisten al programa de clínicas metabólicas del Instituto Salvadoreño del Seguro Social. Rev ALAD 2012;3:310-19
   Google Scholar
• Navarro-Vidal B, Banegas JR, León-Muñoz LM, et al. Achievement of cardiometabolic goals among diabetic patients in Spain. A nationwide population-based study. PLoS One 2013;8:e61549
   PubMed Web of Science ®Google Scholar
• Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013;368:1613-24
   PubMed Web of Science ®Google Scholar
• Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 2013;13:602
   PubMed Web of Science ®Google Scholar
• Braga MF, Casanova A, Teoh H, et al.; Diabetes Registry to Improve Vascular Events [DRIVE] Investigators. Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract 2012;66:457-64
   PubMed Web of Science ®Google Scholar
• Chan JC, Gagliardino JJ, Baik SH, et al.; IDMPS Investigators. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009;32:227-33
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• , ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes: the ADVANCE collaborative group. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Duckworth WC, Evans GW, Gerstein HC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98
   PubMed Web of Science ®Google Scholar
• Abraira C, Duckworth WC, Moritz T; VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2009;11:150-6
   PubMed Web of Science ®Google Scholar
• Bader G, Geransar P, Schweizer A. Vildagliptin more effectively achieves a composite endpoint of HbA1c <7% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Res Clin Pract 2013;100:e78-81
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Colin L, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009;11:589-95
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
   PubMed Web of Science ®Google Scholar
• Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27:318-26
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
   PubMed Web of Science ®Google Scholar